To evaluate liposome formulations for use as intracellular sustained-release drug depots, we have compared the uptake and degradation in rat liver and spleen of liposomes of various compositions, containing as their bulk phospholipid an ether-linked phospholipid or one of several ester-linked phospholipids, by perturbed angular correlation spectroscopy. Multilamellar and small unilamellar vesicles (MLVs and SUVs), composed of egg phosphatidylcholine, sphingomyelin, distearoyl phosphatidylcholine (DSPC), dipalmitoyl phosphatidylcholine (DPPC) or its analog dihexadecylglycerophosphorylcholine (DHPC), and cholesterol plus phosphatidylserine, and containing "'In complexed to nitrilotriacetic acid, were injected intravenously in rats. Recovery of "'In-labeled liposomes in blood, liver, and spleen was assessed at specific time points after injection and the percentage of liposomes still intact in liver and spleen was determined by measurement of the time-integrated angular perturbation factor [G22(o)] of the "'In label. We found that MLVs but not SUVs, having DHPC as their bulk phospholipid, showed an increased resistance against lysosomal degradation as compared to other phospholipid-containing liposomes. The use of diacyl phospholipids with a high gel/liquid-crystalline phase-transition temperature, such as DPPC and DSPC, also retarded degradation of MLV, but not of SUV in the dose range tested, while the rate of uptake of these liposomes by the liver was lower.
Liposomes have been considered for use as a drug delivery system for many years (1) (2) (3) and have in fact recently entered the stage of clinical trials for specific applications (4) . In recent years, efforts have been made to optimize the composition, size ranges, and other properties of liposomes relevant for in vivo applications (for a review, see ref. 5) .
Although small unilamellar vesicles (SUVs) of appropriate lipid compositions may be taken up by nonphagocytic cells, such as hepatocytes (6) , the major mechanism of removal of liposomes from the bloodstream involves endocytosis by the mononuclear phagocyte system, especially for large liposomes (7) (8) (9) . This has led to the recognition that liposomes not only may be considered as a direct drug-delivery system to diseased target cells but also as a vehicle for the creation of intracellular drug depots; thus, in cells other than the ultimate target cells, a sustained release of drug may be effectuated concomitant with degradation of the drugcontaining liposomes (10, 11) . Also, for this type of application, the degree of intracellular stability [i.e., resistance to (intra)lysosomal degradation] becomes an important factor to consider. Recently, it was found that phospholipids containing an ether instead of an ester link between the alkyl chain and the glycerol backbone are highly resistant to metabolic conversion (12, 13) . It has been suggested that such phospholipids may be used to prepare liposomes with an increased resistance to intralysosomal degradation (14) .
An attractive method to measure the integrity of liposomes in blood, cells, or even in a whole organ or animal, without the need to recover the liposomes from the system, is perturbed angular correlation (PAC) spectroscopy (15, 16) . The angular correlation of the two y-rays emitted upon the decay of "'In to 1"'Cd provides information on the tumbling rate of this ion. The high tumbling rate of "'In, chelated in the interior of liposomes [high time-integrated angular perturbation factor, G22(oo)], decreases upon breakdown of the liposomes and the subsequent release of "'In because of the rapid binding of the ion to macromolecules in the surrounding solution. Thus, the fraction of liposomes in the sample that is still intact can readily be measured (15) (16) (17) (18) .
In view of the possible use of liposomes as an intracellular slow-release drug depot system, we used the PAC spectroscopy technique to compare the in vivo rates of degradation in liver and spleen of liposomes of different compositions. We examined the uptake and degradation of both SUVs and multilamellar liposomes (MLVs) of the same compositions. The SUVs were previously shown to be mainly directed to the hepatocytes and the MLV were directed predominantly to the liver macrophages (Kupffer cells) (7) (8) (9) . All the liposome types. investigated contained 50% cholesterol (Chol) to enhance stability in serum (19, 20) and 10% phosphatidylserine (PS) to provide them with a negative charge to prevent aggregation. The balance of the lipid (40%) consisted of either phosphatidylcholine (PC) or beef brain sphingomyelin (SM) or dihexadecylglycerophosphorylcholine (DHPC), an ether-linked analog of dipalmitoyl phosphatidylcholine (DPPC) , that was reported to be resistant to intracellular degradation (12) (13) (14) and also to increase the stability of liposomes in serum (21, 22 Animal Experiments. Eight male Sprague-Dawley rats (190-220 g) per liposome preparation were injected intravenously under light ether anesthesia with 4 ,umol of liposome suspension (total liposomal lipid) in 0.5 ml of HN buffer via the penis vein. At 1, 6, 12, and 24 hr after injection, the rats were killed. Blood samples were taken by cardiac puncture, the livers were excised after perfusion through the portal vein with 60 ml ofphosphate-buffered saline, and the spleens were extirpated. To determine the amount of liposomes remaining in the blood, we assumed a total blood volume per rat of 6.5% body weight. In the measurements of total organ radioactivity, the decay of "1'In was taken into account.
From each rat, =1 ml of blood, 1 g of liver tissue, and the spleen were used immediately to determine the absolute 1"'In uptake and the time-integrated angular perturbation factor [G22(oo)] (17, 18) on the PAC spectrometer at room temperature. To correlate this G22(oo) factor to the percentage intact liposomes, the G22(oo) values of liposomes in HN buffer (0.59 ± 0.02) and of carrier-free "'In in bovine serum (0.19 ± 0.02) were assumed to represent 100% and 0% intact liposomes, respectively.
RESULTS
To assess the solute retention capacity of the liposome preparations in serum, the release of "'In was monitored for 4 days at 37°C (Fig. 1) as a decrease in the time-integrated angular perturbation factor G22(oo), which is equivalent to a decrease in the percentage intact vesicles. As appears from Fig. 1 (25) . SUVs used, the major fraction is cleared from the bloodstream within 6 hr, although there were slight differences in the elimination rates of the various liposome types tested. SUVs containing phospholipids with higher phase-transition temperatures, such as DSPC, DPPC, and DHPC, are cleared less rapidly from the bloodstream than those containing lower phase-transition temperature phospholipids, like egg PC and SM.
The liver uptake of SUVs was inversely correlated with blood elimination (Fig. 3A) . The egg PC-containing liposomes "'In-labeled SUVs per 100 g of body weight. The rats were killed 1, 6, 12, and 24 hr after injection and a sample of =1 ml of blood was taken from the heart and radioactivity was determined. Total radioactivity remaining in blood was estimated by assuming a total blood volume of 6.5% of the rat's body weight. especially were taken up relatively rapidly, reaching maximal amounts in the liver only 1 hr after injection of the liposomes. The DSPC-, DPPC-, and DHPC-containing SUVs did not reach maximal uptake values until 12 hr after injection. For all these liposome types, the liver-associated fraction decreased between 12 and 24 hr after injection. No difference in liver uptake was observed between the DHPC-and DPPC-containing SUVs. Fig. 3B shows the percentage of intact vesicles in the liver. For DHPC-, DPPC-, and SM-containing SUVs this is only -30% within the first hour after injection. For egg PC and DSPC-containing SUVs, however, the fraction of intact vesicles is =70% after 1 hr and decreases to 30% between 1 and 6 hr after injection. Between 6 and 24 hr after injection, the proportion of intact vesicles in the liver further decreases only very slowly for all SUV types tested.
Liposome uptake is much lower in the spleen than in the liver (Fig. 4) . Clearly, the liposome types that were taken up the least avidly by the liver-i.e., DSPC-, DPPC-, and DHPC-containing SUVs-showed the highest uptake by the spleen. This may be due to the increased spillover from the liver under these circumstances. The percentage of intact vesicles in the spleen varied between 30% and 50% at 1 hr after injection and decreased gradually in the following 24 hr for all liposome preparations (Fig. 4B ).
As shown in Table 1 , the total recovery of liposomal label Rats were injected intravenously with 2 ,umol of "'In-labeled SUVs per 100 g of body weight and sacrificed 1, 6, 12, and 24 hr after injection, at which time total recovery of radioactivity in liver, spleen, and blood was determined. Results are averages of two rats. in liver, spleen, and blood decreases from between 84% and 96% at 1 hr to between 54% and 71% of the injected dose at 24 hr after injection.
We do not consider it very likely that the extensive initial release of "1in reflects a proportional chemical degradation of the liposomes in view of our earlier observations on the metabolic conversion of liposomal lipids (26) . Physical disturbance-e.g., due to extensive interaction of the liposomal membranes with (lysosomal) proteins-is probably more likely to cause the rapid initial release of 1"'In. The (Fig. 5A) and degradation (Fig. SB) of various types of injected MLVs. Only 1 hr after injection, maximal liver uptake is attained, in contrast to the more slowly eliminated SUVs. Egg PC-containing MLVs are taken up more avidly by the liver than either DPPC-or DHPC-containing vesicles. Similar to what we observed for the SUVs, we noticed also for MLVs a gradual decrease in total label content, particularly of the liver. Also, with respect to intracellular degradation, the egg PC liposomes show a higher rate of degradation than either the DPPC or the DHPC liposomes (Fig. 5B) . During the first hour after injection, 10-35% of the encapsulated "'In is released in the liver. From then on, label release proceeds more gradually with average rates between 3.0%/hr for DSPC and 0.4%/hr for DHPC during the first 24 hr. The slower phase of the label release presumably reflects metabolic degradation of the liposomes, while the rapid initial phase is probably mostly accounted for by physicochemical effects on the outermost bilayer. The DHPC MLVs are apparently more resistant to breakdown than DPPC MLVs. One day after their uptake by liver cells, only 35% of the "'In label has leaked from the DHPC MLVs, whereas 60% has been released from the DPPC MLVs. After 2 days, these values are 55% and 70%, respectively.
In the spleen, the uptake of egg PC-containing MLVs is much lower than that of DHPC-or DPPC-containing MLVs (Fig. 6A) . Also, in this organ, just as in the liver, the DHPC MLVs appear to be the most stable liposome type (Fig. 6B) . In addition, there is an initial rapid release of "'In in the first hour after injection of the liposomes, followed by a second phase of slower release.
DISCUSSION
In recent years, the preparation of stable liposomal slowrelease drug-delivery systems has drawn much attention. The use of ether-linked phospholipids to create stable liposomes was suggested several years ago (14) . More recently, the use of polymerizable liposomes has also been considered as an alternative strategy for the preparation of liposomes that are resistant to degradation (27) (28) (29) . However, thus far no studies have been published showing an increased solute retention capacity for polymerized as compared to normal liposomes, and reports dealing with ether phospholipid liposomes mainly focus on the extension of the circulatory half-life and increased resistance against serum-induced degradation (14, 21, 22) . None of these reports, however, has examined the actual intracellular stability of these liposomes.
One method to assess the integrity of liposomes involves the relief of self-quenching of carboxyfluorescein encapsulated in liposomes in high concentrations (>30 mM). The observed increase in fluorescence upon leakage of the carboxyfluorescein from the liposomes is a measure of the fraction of the liposomes degraded (30) . Although this method is very convenient for measuring liposome stability in buffer and serum, it is less suitable for measuring intracellular liposome breakdown. The use of PAC spectroscopy, on the other hand, has in recent years proven to be a reliable method to simultaneously assess uptake and degradation of liposomes in whole organs and even in small animals, without the need for prior tissue homogenization or label extraction. Hence, this technique was chosen to examine the in vivo disposition of liposomes in our studies.
The PAC technique requires that the liposomes contain a relatively large amount of '11In (10 Firstly, it is unlikely that much "1'In had leaked from the liposomes during their stay in the circulation, since the liposomes of all compositions used were cleared so fast that within 6 hr after injection the blood compartment was virtually devoid of 1"'In label. Secondly, the percentage of intact vesicles in the blood, as measured by the G22(oo) parameter, was consistently higher than 90%, indicating that the leakage of "'In from the liposomes in our experiments is low indeed. Thirdly, preliminary experiments showed that nonentrapped "'In had a half-life in blood of -3 hr, with the "'In appearing rapidly in the urine. Since the recovery of "'In label in blood, liver, and spleen amounted to at least 80% of the injected dose during the first uptake phase, not much "'In could have escaped from the body during the time the liposomes were in circulation. Therefore, we feel confident that virtually all the "'In remained associated with the liposomes until their uptake by the target cells.
From our results we conclude that, in spite of the reported resistance of DHPC toward lysosomal degradation, in particular against the action of phospholipase A2 (12, 13) , the use of this lipid instead of its ester analog DPPC for the preparation of SUVs does not lead to an increase of intracellular liposomal stability. As was shown, the blood disappearance as well as the uptake by liver and spleen and the in vitro serum stability were similar for both the DHPC-and DPPCcontaining SUVs. Also, the rate of degradation, as reflected in the percentage intact liposomes in liver and spleen, did not differ appreciably. In MLVs, however, the use of DHPC as a bulk phospholipid instead of DPPC substantially improved the intracellular stability ofthese liposomes. Both in liver and in spleen, DHPC-containing MLVs were the most stable liposomes tested.
There may be several reasons why the stabilizing effect of DHPC was so much more apparent for MLV than for SUV.
Firstly, the degradative capacity of the liver for the types of (31) .
We observed that the radioactivity recovered in the liver as well as in the spleen reaches a maximum between 6 and 12 hr after injection of the SUVs, and within 1 hr for the MLVs. The subsequent decrease in radioactivity reflects an organ redistribution of the label as indicated by the accumulation of radioactivity in the kidneys and at later time points in the urine. No 1"'In label was excreted in the bile (data not shown). We also noticed that the G22(oo) value is low in the kidney but high in the urine. The "'In secreted by the liver cells into the bloodstream after intrahepatic degradation of the liposomes is probably bound to protein, giving rise to a low G22(oo) value. In the kidneys, the "'In is stripped from the protein, as a result of which the tumbling rate increases [high G22(oo) value]; it is later excreted into the urine.
In conclusion, the use of ether-linked phospholipids offers an advantage over the ester-linked equivalent in terms of increased liposome stability in the case of MLVs but not of SUVs. DHPC-containing MLVs may be useful as a sustained-release drug-delivery system, especially for drugs exerting their therapeutic effect in the liver. After uptake and degradation of such drug-loaded MLVs by Kupffer cells, the entrapped drug may then be released by the cells, thus providing sustained drug availability..
